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Abstract: Six newly synthesized heterocyclic (2-nitrophenyl)piperazines, with a spe-
cific structure of the heteroaryl group, which mimics the catechol moiety of dopamine
(benzimidazoles and substituted benzimidazoles), were evaluated for their binding af-
finity to rat dopamine (DA), serotonin (5-HT) and 1 receptors. All compounds with a
benzimidazole group had a 5-HT2A/D2 receptors binding ratio characteristic for atypi-
cal neuroleptics (>1, pKi values). Compound 7c, 4-bromo-6-{2-4-(2-nitrophenyl)pi-
perazin-1-ylethyl}-1H-benzimidazole, expressed higher affinities for all receptor
classes than clozapine. Also, it exhibited the best characteristic for atypical neuro-
leptics and presents a compound with the best profile for further in vivo investigations.
Keywords: arylpiperazines, benzimidazoles, dopamine receptors, serotonin recep-
tors, atypical antipsychotic.
INTRODUCTION
One field of intensified research in the area of medicinal chemistry is focused
on the design and synthesis of new antipsychotic drugs (APDs) which would ex-
press a higher therapeutic efficiency and a wider spectrum of action on schizophre-
nia symptoms, with minimized extrapyramidal side effects. Conventional APDs,
acting by a common mechanism of the blocking of the central dopamine (DA) D2
receptors, are generally considered to be effective in the treatment of schizophrenics
with positive symptoms,1 while a group of so-called atypical APDs, such as the pro-
totype drug – clozapine, express increased effectiveness in negative affective symp-
toms, including efficacy in patients resistant to standard therapy.2 The new genera-
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tion of therapeutically successful atypical APDs act as both DA and 5-HT system
stabilizers. They express partial agoinst activity at the 5-HT1A receptors and stronger
antagonism at the 5-HT2A than at the D2 receptors, which is also suggested in litera-
ture as a suitable model of interactions for some newly synthesized DA/5-HT ligands
which are considered for their atypical neuroleptic potential.2–4 Previous studies on
benzimidazole type of dopaminergic/serotonergic ligands5–7 showed that the affin-
ity and DA/5-HT ratio can be fine tuned by small changes in the structure of the
ligand. Following this approach, series of halogenated derivatives of benzimidazoles
and benzimidazole-2-thiones, containing (2-nitrophenyl)piperazine moiety, which
are expected to have APD-like properties, are presented.
EXPERIMENTAL
General
A Boetius PHMK apparatus (VEB Analytic, Dresden, Germany) was used to determine the
melting points (uncorrected). The 1H-NMR spectra were recorded on a Gemini 2000 spectrometer
(Varian, Palo Alto, CA, USA), with CDCl3 as the solvent unless otherwise stated and are reported in
ppm downfield from the internal standard tetramethylsilane. The IR spectra were run on a Perkin
Elmer 457 Grating Infrared Spectrophotometer (Perkin Elmer, Beaconsfield, UK). The mass spectra
were determined using a Finnigan Mat 8230 mass spectrometer (Finnigan, Bremen, Germany).
High-resolution mass spectra were aquired on a Bruker Biflex MALDI TOF (Bruker, Bremen, Ger-
many). For analytical thin-layer chromatography, Merck (Darmstadt, Germany) F-256 plastic-ba-
cked thin-layer silica gel plates were used. Chromatographic purifications were performed on
Merck-60 silica gel columns, 230–400 mesh ASTM, under medium pressure (MPLC). Solutions
were routinely dried over anhydrous Na2SO4 prior to evaporation.
Chemistry
4-(2-Chloroethyl)-2-nitroaniline (1a),8 2-chloro-4-(2-chloroethyl)-6-nitroaniline (1b)7and 2-bro-
mo-4-(2-chloroethyl)-6-nitroaniline (1c)7 were prepared as previously described.
Synthesis of tert-butyl 2-(tert-butoxycarbonyl)amino-4-(2-chloroethyl)phenylcarbamate (3a),
tert-butyl 2-(tert-butoxycarbonyl)amino-3-chloro-5-(2-chloroethyl)phenylcarbamate (3b) and tert-butyl
2-(tert-butoxycarbonyl)amino-3-bromo-5-(2-chloroethyl)phenylcarbamate (3c). Stannous chlo-
ride (47.5 g, 0.23 mol) was added to a solution of either 4-(2-chloroethyl)-2-nitroaniline (1a) or
2-halo-4-(2-chloroethyl)-6-nitroaniline (1b,c) (40 mmol) in absolute ethanol (85 mL). After 4 h at
reflux, the solution was poured onto ice, made alkaline with 5 M NaOH and extracted with EtOAc.
The extracts were dried and the solvent was removed in vacuo. The resulting diamine (2a, 2b or 2c)
was immediately used without further purification. The obtained diamine (2a, 2b or 2c) (21 mmol)
was dissolved at 0 °C in a mixture of dioxane (65 mL) and 1M NaOH (65 mL). To this solution,
di-tert-butyl dicarbonate (6.9 g, 31.5 mmol) was added at 0 °C and after 2 h at this temperature, the
reaction mixture was stirred overnight at room temperature. The excess solvent was evaporated in
vacuo and the residue extracted with CH2Cl2. The obtained product was purified by MPLC using
CH2Cl2 as the eluent. (3a): Yield: 60%; oil;
1H NMR:  1.51, (s, 18H), 3.01 (t, 2H, J = 7.6 Hz), 3.67
(t, 2H, J = 7.6 Hz), 6.61 (s, 1H, NH), 6.80 (s, 1H, NH), 6.96 (dd, 1H, J = 6.2 Hz, J = 2Hz, ArH),
7.35–7.43 (m, 2H, ArH). (3b): Yield: 88%; m.p. 112 °C; 1H NMR:  1.52 (s, 18H), 2.93 (t, 2H, J =
7.4 Hz), 3.65 (t, 2H, J = 7.4 Hz), 6.24 (s, 2H, NH), 6.99 (d, 1H, J = 2 Hz, ArH), 7.17 (s, 1H, ArH).
(3c): Yield: 96 %; m.p. 121 °C; 1H NMR:  1.52 (s, 18H), 2.93 (t, 2H, J = 7.4 Hz), 3.65 (t, 2H, J = 7.6
Hz), 6.27 (s, 2H, NH), 7.14 (d, 1H, J = 2 Hz, ArH), 7.21 (s, 1H, ArH).
General procedure for the synthesis of tert-butyl 2-(tert-butoxycarbonyl)amino-4-{2-4-(2-ni-
trophenyl)piperazin-1-ylethyl}phenylcarbamate (4a) and tert-butyl 2-(tert-butoxycarbonyl)ami -
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no-3-halo-5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}phenylcarbamates (4b,c). To a solution of 10.0
mmol of 1-(2-nitrophenyl)piperazine in 50.0 mL DMF, 12.0 mmol of either tert-butyl 2-(tert-bu-
toxycarbonyl)amino-4-(2-chloroethyl)phenylcarbamate (3a) or tert-butyl 2-(tert-butoxycarbo-
nyl)amino-3-halo-5-(2-chloroethyl)phenylcarbamate (3b,c), 6.0 g K2CO3 and 0.1 g of KI were
added. The mixture was stirred at 80 °C for 12 h. After cooling, the precipitate was removed and the
filtrate evaporated in vacuo. The residue was dissolved in CH2Cl2 and the obtained products puri-
fied by MPLC using CH2Cl2 as the eluent. (4a): Yield: 58 %; oil;
1H NMR:  1.52 (s, 18H, CH3),
2.65–2.70 (m, 6H); 2.78–2.84 (m, 2H); 3.08–3.13 (m, 4H); 6.60 (s, 1H, NH); 6.76 (s, 1H, NH);
6.94–7.18 (m, 3H, ArH); 7.32–7.52 (m, 3H, ArH); 7.62 (dd, J = 6.4 Hz, J = 1.6 Hz, 1H, ArH). (4b):
Yield: 72%; oil; 1H NMR:  1.52 (s, 18H), 2.69–2.72 (m, 8H), 3.10–3.14 (m, 4H), 6.41 (s, 2H, NH),
6.98–7.18 (m, 4H, ArH), 7.44–7.53 (m, 1H, ArH), 7.77 (dd, 1H, J = 6.6 Hz, J = 1.6 Hz, ArH). (4c):
Yield: 79%; oil; 1H NMR:  1.52 (s, 18H), 2.64–2.69 (m, 8H), 3.08–3.13 (m, 4H), 6.24 (s, 2H, NH),
6.98–7.08 (m, 2H, ArH), 7.19–7.25 (m, 2H, ArH), 7.44–7.52 (m, 1H, ArH), 7.77 (dd, 1H, J = 6.6 Hz,
J = 1.8 Hz, ArH).
General procedure for the synthesis of 2-amino-4-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}phe-
nylamine (5a) and 2-amino-3-halo-5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}phenylamines (5b and
5c). Hydrochloric acid (37%, 10 mL) was added under stirring to a solution of either tert-butyl
2-(tert-butoxycarbonyl)amino-4-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}phenylcarbamate (4a) or
tert-butyl 2-(tert-butoxycarbonyl)amino-3-halo-5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}phenylca-
rbamate (4b,c) (5.0 mmol) in 20 ml EtOH at RT. After 60 min, the solvent was evaporated in vacuo. The
residue was extracted with a mixture of 20 ml 10 % NaHCO3 and 20 mL chloroform, the organic phase
was separated, dried over Na2SO4, and evaporated in vacuo. The obtained products were used without
further purification for the synthesis of compounds 6a–c and 7a–c.
Synthesis of 5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}-1,3-dihydro-2H-benzimidazole-2-thi-
one (6a) and 4-halo-6-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}-1,3-dihydro-2H-benzimidazole-2-thi
ones (6b,c). Carbon disulfide (0.24 mL, 4 mmol) and KOH (0.25 g in 0.6 mL water) were added to 2
mmol of diamine (5a,b or c) in 10 mL EtOH. After refluxing for 3 h, 0.3 mL of acetic acid in 3.3 mL
water were added. The solvent was removed in vacuo and the residue purified by silica gel column
chromatography using a 0–5% MeOH gradient in CH2Cl2. (6a): Yield: 50 %; m.p.: 238–240 °C; IR
(cm-1): 1188, 1343, 1461, 1490, 1518, 1603, 2834, 2948, 3069; 1H NMR (DMSO-d6):  2.49–2.56
(m, 2H); 2.76–2.83 (m, 4H); 2.97–3.01 (m, 6H); 6.98–7.16 (m, 4H, ArH); 7.32 (dd, J = 7.2 Hz, J = 1
Hz, 1H, ArH); 7.58 (t, J = 2.6 Hz, 1H, ArH); 7.78 (d, J = 6.8 Hz, 1H, ArH); 12.47 (s, 2H, NH); MS
m/e 384.142 (M+1); C19H21N5O2S. (6b): Yield: 87 %; m.p. 249 °C; IR (cm
-1): 1196, 1348, 1488,
1515, 1607, 2829, 3446; 1H NMR (DMSO-d6):  2.50–2.56 (m, 6H), 2.80 (t, 2H, J = 8 Hz), 2.99 (s,
4H), 6.98 (d, 1H, J = 1.2 Hz, ArH), 7.09–7.16 (m, 2H, ArH), 7.29–7.33 (m, 1H, ArH), 7.58 (t, 1H, J =
7 Hz, ArH), 7.79 (dd, 1H, J = 8.6 Hz, J = 1.4 Hz, ArH), 12.82 (s, 2H, NH); MS: m/e 370.1 (100),
417.1 (M+); C19H20ClN5O2S. (6c): Yield: 69 %; m.p. 256 °C; IR (cm
-1): 1196, 1343, 1485, 1518,
1604, 2826, 3035; 1H NMR (DMSO-d6):  2.49–2.56 (m, 6H), 2.80 (t, 2H, J = 7.8 Hz), 2.99 (s, 4H),
7.01 (d, 1H, J = 1.2 Hz, ArH), 7.12 (t, 1H, J = 7 Hz, ArH), 7.23 (d, 1H, J = 1.2 Hz, ArH), 7.31 (d, 1H,
J = 8 Hz, ArH), 7.56 (m, 1H, ArH), 7.79 (dd, 1H, J = 9 Hz, J = 1.8 Hz, ArH), 12.79 (s, 2H, NH); MS:
m/e 462.9 (100) (M+1); C19H20BrN5O2S.
Synthesis of 5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}-1H-benzimidazole (7a) and 4-ha-
lo-6-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}-1H-benzimidazoles (7b,c). 2 mmol of diamine (5a,b
or c) and 0.44 mL (7.3 mmol) of 98% formic acid were heated in an oil bath at 100 °C for 2 h. After
cooling to ambient temperature, 15 mL of 10% NaHCO3 were added and the product extracted with
CH2Cl2. The solvent was removed in vacuo and the residue purified by silica gel column chroma-
tography using a 0–3% MeOH gradient in CH2Cl2. (7a): Yield: 88%; oil; IR (cm
-1): 1180, 1345,
1518, 1603, 2830, 3089; 1H NMR (DMSO-d6):  2.92–3.00 (m, 6H), 2.92–3.00 (m, 2H); 3.11 (t, 4H,
J = 5 Hz), 7.00–7.08 (m, 1H, ArH), 7.11–7.17 (m, 2H, ArH), 7.43–7.52 (m, 2H, ArH), 7.60 (d, 1H, J
= 8.4 Hz, ArH), 7.76 (dd, 1H, J = 1.6 Hz, J = 6.6 Hz, ArH), 8.08 (s, 1H, CH), 12.30 (s, 1H, NH); MS:
N-(-2-NITROPHENYL)PIPERAZINE DERIVATIVES 431
m/e 352 (100) (M+1); C19H21N5O2. (7b): Yield: 85 %; m.p. 86 °C; IR (cm
-1): 1345, 1519, 1604,
2833, 3432; 1H NMR (DMSO-d6):  2.82 (s, 6H), 2.93 (s, 2H), 3.10 (s, 4H), 7.12–7.20 (m, 2H,
ArH), 7.33–7.42 (m, 2H, ArH), 7.57–7.65 (m, 1H, ArH), 7.82 (dd, 1H, J = 6.4 Hz, J = 1.6 Hz, ArH),
8.26 (s, 1H, CH), 12.75 (s, 1H, NH); MS: m/e 385.0 (100) (M+); C19H20ClN5O2. (7c): Yield: 98 %;
m.p. 82 °C; IR (cm-1): 1197, 1345, 1486, 1518, 1603, 2825, 3094; 1H NMR (DMSO-d6): 
2.58–2.65 (m, 6H), 2.87 (t, 2H, J = 8 Hz), 3.00 (s, 4H), 7.08–7.16 (m, 1H, ArH), 7.29–7.33 (m, 2H,
ArH), 7.43 (s, 1H, ArH), 7.54–7.63 (m, 1H, ArH), 7.78 (dd, 1H, J = 6.8 Hz, J = 1.4 Hz, ArH), 8.24 (s,
1H, CH), 12.82 (s, 1H, NH); MS: m/e 430.9 (100) (M+1); C19H20BrN5O2.
Membrane preparation, binding assays and data analysis
Specific binding affinities (pKi, values, Table I) of several newly synthesized (2-nitrophe-
nyl)piperazines and clozapine were determined exactly as described previously9 by measuring the
extent of displacement of 3H-labelled specific ligands purchased from Amersham Buchles GmbH
(3Hspiperone for D2, 
3H8-OH-DPAT for 5HT1A, 
3Hketanserin for 5HT2A and 
3Hprazosine
for 1 receptors) from rat striatal or cortical synaptosomes with a range of concentrations (10
-5–10-9
M) of the selected compound. Non-specific binding was measured in the presence of (+)-butaclamol
(D2), serotonine (5HT1A), ketanserin (5HT2A) and prazosine (1). The retained radioactivity was
measured by introducing dry filters and 5 mL toluene-based scintillation liquid and counted in a
1219 Rackbeta Wallac scintillation counter.
Competition binding curves were constructed and analyzed by "GraphPad Prysm" (v. 4.0.).
TABLE I. Chemical structure and pKi values of the ligands
No R pKi  SEM 5HT2A/D2 binding ratio
D2 5HT1A 5HT2A 1
6a H 7.55±0.20 6.76±0.18 7.09±0.06 7.45±0.11 0.94
6b Cl 7.08±0.05 6.74±0.08 6.83±0.05 7.23±0.07 0.97
6c Br 6.94±0.09 6.68±0.05 6.84±0.11 7.64±0.09 0.99
No R pKi  SEM 5HT2A/D2 binding ratio
D2 5HT1A 5HT2A 1
7a H 7.71±0.05 6.37±0.14 7.79±0.10 7.94±0.06 1.01
7b Cl 7.38±0.08 6.50±0.06 7.60±0.06 7.71±0.11 1.03
7c Br 7.02±0.05 6.81±0.08 8.00±0.02 8.01±0.10 1.14
Clozapine 6.83±0.10 5.93±0.08 7.88±0.12 7.66±0.10 1.15
Values are the means of 3–4 independent experiments done in duplicate performed at five competing
ligand concentrations (10-5–10-9 M) with 3Hspiperone (D2), 
3H8-OH-DPAT (5HT1A), 
3Hketa-
nserin (5HT2A) or 
3Hprazosine (1).
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RESULTS AND DISCUSSION
Several new 5-{2-4-(2-nitrophenyl)piperazin-1-ylethyl}-1,3-dihydro-2H-ben-
zimidazole-2-thiones and 5-{2-[-(2-nitrophenyl)piperazin-1-yl]ethyl}-1H-benzimi-
dazoles (compounds 6a–c and 7a–c, respectively) were synthesized as shown in
Scheme 1. In short, 4-(2-chloroethyl)-2-nitroaniline (1a) or 4-(2-chloroethyl)-2-ha-
lo-6-nitroaniline (1b,c) were reduced with stannous chloride in absolute ethanol, and
the resulting diamines 2a–c were converted into di-tBOC derivatives 3a–c, using
di-tert-butyl dicarbonate. The compounds readily alkylated 1-(2-nitrophenyl)piperazi-
ne in the presence of potassium carbonate and potassium iodide in DMF. Diamines
5a–c were obtained by hydrolyzing the di-tBOC derivatives with 4M HCl in ethanol.
Benzimidazole-2-thiones 6a–c and benzimidazoles 7a–c were synthesized from the
corresponding diamines with CS2/KOH in EtOH and formic acid, respectively.
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Scheme 1. Pathways for the synthesis of the ligands.
In all compounds labeled as No. a. the R substituent is H, in compounds labeled as No. b. the R
substituent is Cl and in compounds labeled as No. c. the R substituent is Br.
a) SnCl2, EtOH; b) 1M NaOH, O(CO2C(CH3)3)2; c) DMF, KI, K2CO3,
1-(2-nitrophenyl)piperazine; d) EtOH, 4M HCl, 60 °C; e) EtOH, KOH, CS2; f) formic acid.
The binding affinities were evaluated by specific in vitro assays for the DA
(D2), 5-HT (5-HT1A and 5-HT2A) and 1-adrenergic receptors. These receptors
were chosen in accordance to the serotonin–dopamine hypothesis of schizophrenia
and with regards to their anticipated roles in the action of atypical APDs.3,4 The
significance of ligand interaction with adrenergic receptors was also suggested, as
their blockage may stabilize dysregulated central dopaminergic systems in schizo-
phrenia.10 Specific binding affinities (pKi values, Table I) of the newly synthesized
compounds and clozapine, the prototype of atypical APD, were determined by
measuring the extent of displacement of 3H-labelled specific ligands from rat
striatal or cortical synaptosomes with a range of concentrations of the com-
pounds.9,11
In previous studies on ligand–D2 dopamine receptor interactions, it was no-
ticed that the binding affinity depends substantially on the structure of the arylpi-
perazine part of molecule.6 In addition to general structural requirements, it was
clearly shown that substituents able to participate in hydrogen bond formation (ni-
tro or methoxy) in position 2 of the phenyl ring in the piperazine part of a ligand
forming one more hydrogen bond, with Trp 182 (VI.48) (an amino acid highly con-
served through the A class of the G protein-coupled receptor family), increase the
binding affinities.5 Additionally, a study of the effects of halogens on the electron
density of the benzimidazole benzene ring raised the hypothesis that electron-with-
drawing substituents have a strong influence on the electrostatic surface potential
of a ligand, which is an important factor in the interaction with the receptors bind-
ing pocket.7 Our leading idea was to combine those two effects by the synthesis of
halogenated (2-nitrophenyl)piperazines and to compare their binding affinities
with the parent, non-substituted (2-nitrophenyl)piperazines.
All compounds (parent, benzimidazole-2-thione and benzimidazole, and ha-
logen substituted ligands) expressed a higher affinity for the D2 and 5HT1A recep-
tors comparing to clozapine, while only benzimidazole series of the compounds
showed increased affinity for the 1-adrenergic receptor. Binding potency towards
5HT2A receptors, similar to clozapine, were expressed only by (2-nitrophenyl)pi-
perazines with the benzimidazole moiety, where compound 7c showed a somewhat
higher affinity for the 5HT2A receptors than clozapine pKi (Ki) values of 8 (10
nM) and 7.88 (13.2 nM), respectively.
The results of the investigations justify our hypothesis that the introduction of
a halogen atom in the heterocyclic, benzimidazole-like, part of the (2-nitro-
phenyl)piperazine molecule would result in a higher affinity for D2 DAR. On the
other hand, the benzimidazole series of the ligands showed a binding potency to-
wards 5HT2A receptors similar to that of clozapine and all of them showed a
5HT2A/D2 binding ratio characteristic for atypical APDs (>1, pKi values). Only in
the case of compound 7c the introduction of the halogen atom result in an increase
of the selectivity towards 5HT2A receptors.
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Taking all this into account, 4-bromo-6-{2-4-(2-nitrophenyl)piperazin-1-ylet-
hyl}-1H-benzimidazole (7c) exhibited the most suitable 5HT2A/D2 binding ratio
(1.14, pKi value) and showed all prerogatives characteristic for atypical neuroleptics
and suggests this compound to be a good pretender for further in vivo testing.
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Sintetisano je {est heterocikli~nih (2-nitrofenil)piperazina sa specifi-
~nom heteroaril grupom, koja podra`ava kateholsku grupu dopamina (benzimidazoli
i supstituisani benzimidazoli), i ispitan je wihov afinitet ka dopaminskim, sero-
toninskim i 1 receptorima. Sva jediwewa sa benzimidazolskim grupama su pokazala
5-HT1A/D2 odnos vezivawa karakteristi~an za atipi~ne neuroleptike (>1, pKi vred-
nosti). Jediwewe 7c, 4-bromo-6-{2-4-(2-nitrofenil)piperazin-1-iletil}-1H-benzi-
midazol, pokazalo je izra`eniji afinitet ka svim klasama receptora u pore|ewu sa
klozapinom i tako|e predstavqa jediwewe sa najboqim karakteristikama za daqa in
vivo istra`ivawa.
(Primqeno 7. aprila, revidirano 15. decembra 2006)
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